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Abstract
Although the HIV pandemic is witnessing a decline in the number of new infections in most regions of the world, 
the Middle East and North Africa (MENA) has a rapidly growing HIV problem. While generating HIV data has 
been consistently increasing since 2005, MENA’s contribution to the global HIV literature is just over 1% and the 
existing evidence often falls behind the academic standards. Several factors could be at play that contribute to 
the limited quantity and quality of HIV data in MENA. This editorial tries to explore and explain the barriers to 
collecting high-quality HIV data and generating precise estimates in MENA. These barriers include a number of 
logistic and socio-political challenges faced by researchers, public health officials, and policy-makers. Looking at 
successful regional HIV programs, we explore examples were policies have shifted and lessons could be learned 
in developing appropriate responses to HIV across the region.
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The Middle East and North Africa (MENA)[1] covers an extensive region extending from Morocco to Iran and includes a number of low-, middle-, and high-income 
countries comprising 10% of the world’s 15-49 population.1-3 
The socio-cultural, political, and logistical context of the region 
has created several barriers to addressing public health issues, 
effectively.4 In particular, adopting appropriate approaches 
to tackle sexually transmitted infections – HIV in particular 
– often leads to heated and controversial debates. Although 
the HIV pandemic is witnessing a decline in the number of 
new infections in most regions of the world, the MENA is 
one of the regions the world with a rapidly increasing HIV 
epidemic.4 Unlike sub-Saharan Africa where new annual HIV 
infections have declined by 41% since 2000, HIV transmission 
rates in the MENA rose by 17% during the same period; the 
second greatest growth in the world. Similarly, while the 
number of AIDS-related death have declined by 34% in sub-
Saharan Africa since 2000, they indicate a 234% increase in 
the MENA; the greatest growth globally (Figure 1).5,6 
Despite the growing HIV problem in the MENA, its 
contribution to the global HIV literature is very limited.7 
Moreover, as outlined in Figure 2, most of the contribution 
of MENA countries to HIV-related literature is coming 
from only a few countries (eg, 60% of the peer-reviewed 
publications indexed in PubMed are published in Iran [805 
papers], Pakistan [464 papers], Egypt [196 papers], and 
Sudan [189 papers]). Is it the quality of HIV research that 
does not meet the required standards of academic journals 
and remains unpublished? Is this small contribution due 
to the poor human capital and a limited number of trained 
and experienced staff to conduct high-quality research 
and report their findings? Alternatively, are most MENA 
countries struggling with financing HIV research or is there 
a systematic politically- or ideologically-driven approach that 
limits generating high-quality HIV data? Are the ongoing 
and expanding conflicts in parts of the region making the 
HIV epidemic look like a “trivial” problem to policy-makers? 
Would strategies be shifted when policy-makers are provided 
with high-quality and solid evidence? In this editorial, we try 
to assess these questions and provide potential action steps in 
addressing the challenges around collecting high-quality and 
frequent HIV data in MENA countries.
Limited HIV Data for Key Populations at Risk of HIV
In the MENA, the epidemic is believed to be driven by sexual 
and drug-related risky behaviours of key populations at risk of 
HIV. Main affected populations in the MENA are people who 
inject drugs (PWID), men who have sex with men (MSM), 
female sex workers (FSWs), and their sexual and injecting 
partners.1,2,4 In such concentrated epidemics, the estimates 
of HIV prevalence relies on the prevalence of HIV in each 
key at-risk population and the size of low- and high-risk 
populations. In the MENA region, however, data on HIV 
prevalence among key populations is unavailable in several 
low- and high-income countries (eg, Bahrain, Iraq, Kuwait, 
Libya, Oman, Qatar, Saudi Arabia, South Sudan, Syria, and 
the UAE).4,8 Moreover, the existing evidence do not portray 
the real picture of new HIV infections in the region and are 
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prone to underestimation biases due to their reliance on 
the poor, infrequent, and non-representative (eg, facility-
based) surveillance systems within the Ministries of Health.4 
Indeed, only three countries (ie, Djibouti, Iran, and Morocco) 
in the MENA have been reported to have a relatively stable 
and functioning HIV surveillance system.4,8,9 Moreover, 
no country has managed to have more than three rounds 
of integrated bio-behavioral surveillance surveys (IBBS) 
among key populations. Egypt, Lebanon, and Tunisia are the 
only three countries to have conducted IBBS in all three key 
populations (ie, FSWs, MSM, PWID).4,8 Additionally, several 
key populations (eg, FSWs, MSM) continue to be criminalized 
and are excluded from surveillance programs due to several 
socio-political sensitivities.4,7 Other populations such as 
foreign migrant workers, military personnel, refugees, street 
children, and internally displaced individuals are also often 
overlooked or missed in monitoring and evaluation sectors.4,8 
Therefore, great uncertainties exist around estimating the size 
of key populations at risk of HIV in the MENA, MSM, and 
FSWs in particular.1,10
Limited HIV Data for the General Population
A significant problem affecting the completeness, validity, 
and reliability of HIV data in the MENA is the absence of 
precise or evidence-based population data. The region has 
been facing several conflicts, wars, and uprisings in the past 
few years. The recent ongoing forced displacement of civilians 
combined with the chaotic economic and socio-political 
situations has created one of the worst humanitarian crises 
in the past century. Thousands of people have been killed, 
wounded, or forced into migrations inside and outside their 
countries. In the last 10 years, several countries have been 
directly and indirectly involved in conflicts and civil wars 
in the MENA (eg, Bahrain, Egypt, Iraq, Lebanon, Palestine, 
Saudi Arabia, Somalia, Sudan, Syria, and Yemen).11 In Syria 
for example, approximately 8.7 million people are estimated 
to be displaced internally, and 4.8 million to have left Syria by 
the end of 2015.12 In Iraq, as many as 3.9 million Iraqis were 
internally displaced by mid-2015.12 Therefore, estimating the 
size of the population or defining the population – which 
are key indicators in calculating HIV rates – remain very 
challenging and result in impaired quality of estimates.13,14 
Furthermore, forced displacement may contribute to the 
vulnerability of refugees to HIV; survival sex practices in 
exchange for food and resources (eg, housing, jobs) have 
been reported from refugees across various settings including 
Lebanon, Jordan, and Cyprus.15-18 
Given the challenges around reaching precise estimates, 
Figure 2. HIV-Related Publications in Different Countries Across the Middle East and North (MENA) Africa Region (Peer-Reviewed Publications 
Indexed in PubMed by July 2016).
Figure 1. Percentage Change in the Estimated Annual Number of New HIV Infections and AIDS-related Death by World Region, 2000-2015.5,6
 
5
90
-22
-40 -41
17
-25
135
-36
-19
-34
234
-100
-50
0
50
100
150
200
250
Western &
Central Europe &
North America
Eastern Europe &
Central Asia
Latin America &
Caribbean
Asia & Pacific Sub-Saharan
Africa
MENA
%
 C
ha
ng
e 
(2
00
0-
20
15
)
World Regions
New HIV Infections AIDS-Related Deaths
 
4 9 15 21 25 26 29 38 38 40
47 54 54 60 62 79
87 103
131
181189196
464
805
0
100
200
300
400
500
600
700
800
900
Pa
le
st
in
e
Sy
ria
Ba
hr
ai
n
Q
at
ar
So
ut
h 
Su
da
n
O
m
an
U
AE Ira
q
Ye
m
en
Al
ge
ria
Ku
w
ai
t
Jo
rd
an
Li
by
a
So
m
al
ia
Dj
ib
ou
ti
Le
ba
no
n
Tu
ni
sia
Af
gh
an
ist
an
M
or
oc
co
Sa
ud
i A
ra
bi
a
Su
da
n
Eg
yp
t
Pa
ki
st
an Ira
n
N
um
be
r o
f H
IV
-r
el
at
ed
 P
ub
lic
at
io
ns
MENA Countries
Karamouzian et al
International Journal of Health Policy and Management, 2017, 6(2), 65–69 67
adjustment values for the plausibility bounds in most 
countries in the MENA are obtained through consultancies 
with national HIV experts, which would have implications for 
the validity and reliability of the estimates and is susceptible 
to some limitations, misinterpretations, and subjectivities. 
Indeed, the evidence on HIV data points to a wide discrepancy 
between estimated cases of HIV and official national statistics; 
leading to contradictory interpretations of the course of the 
HIV epidemic in the region. By the end of 2015, the registered 
number of people living with HIV (PLHIV) across all MENA 
countries were far less than the estimated national numbers.6 
For example, while Iran’s Ministry of Health reported about 
31 000 registered PLHIV cases, estimates were suggesting 
73 000 PLHIV to be living in Iran.19,20 Moreover, figures in 
some settings are incredibly low and raise concerns about 
their reliability. For example, in Egypt with a population of 82 
million, the official number of people living with HIV (PLHIV) 
was estimated at around 11 00021; a figure much lower than 
that of Sudan (around 56 000 PLHIV in a population of 38 
million)22 or Morocco (around 24 000 PLHIV in a population 
of 33 million).23 
Social and Political Will for a Change: Easier Said Than 
Done
The beginning phases of HIV discovery was overshadowed 
with the “not in our land” policy, and the MENA was assumed 
to be socio-culturally “immune” to the HIV epidemic. HIV 
was assumed to be less prevalent in the MENA due to the 
dominant practice of Islamic rituals (eg, circumcision and 
ablution) and conservative socio-cultural settings (eg, 
stigmatizing and prohibiting alcohol consumption, substance 
abuse, pre/extramarital sex, and homosexuality).24,25 There 
is a wide perception that the socio-cultural and political 
sensitivities associated with HIV research in the MENA 
as well as structural-level HIV-related stigma, may restrict 
access to HIV-related data and create barriers in conducting 
HIV research in the region.26 
Indeed, making decisions to address HIV in concentrated 
epidemics – where key populations are at the core of the 
preventative interventions – could be a real challenge in 
contexts where the existence of most key populations (eg, 
MSM, FSWs) is denied. Therefore, the political cost of 
allocating public funds to deal with their needs and problems 
could be concerning or “politically unsafe” for many public 
health officials; leading to underfunding of HIV research 
at the national level.1,4,25-27 In 2010 for example, per capita 
domestic governmental spending on HIV ranged between 
less than five cents in the poorest to just over $1 in the 
richest countries in the region.1,28 This placed the MENA at 
the bottom of the world regions in public fund spending on 
HIV.1,28 As a result, most of the quality research conducted so 
far has mainly been funded by international funders such as 
the Global Fund to Fight AIDS, tuberculosis (TB), and Malaria 
(GFATM) which represents over 70% of the support for HIV/
AIDS in the MENA.1,29 The US National Institutes of Health 
(NIH), Bethesda, MD, USA is another international funder 
that has recognized the need to scale up HIV research in the 
MENA and supported novel HIV research in Egypt, Lebanon, 
Morocco, and Tunisia. However, recent revisions made to 
the financing criteria of GFATM have raised concerns about 
the future of these sources of support for some countries in 
the MENA (eg, Tunisia, Morocco).1 Furthermore, several 
middle-income countries in the MENA are ineligible for 
other international funds (eg, US President’s Emergency Plan 
for AIDS Relief - PEPFAR or bilateral support of other donor 
nations).1,8,30 Regardless, such international investments have, 
indeed, led to improvements in the quality of HIV research 
by training national experts on state-of-the-art approaches 
for community-based HIV surveillance surveys among key 
populations (eg, respondent driven sampling approaches) 
and hence resulted in an increase in the improved visibility of 
HIV research from the MENA in high impact peer-reviewed 
journals.7,26 Nonetheless, despite the increasing body of 
evidence on HIV research in the MENA since 2005, it is still 
Table. Challenges in Generating High-Quality and Frequent HIV Data in the MENA and Action Steps Needed to Improve the Quality and Quantity of HIV 
Data in the MENA
Challenges Action Steps
Limited studies on key populations at risk of HIV
• Acknowledging the burden of the epidemic and recognizing key populations as a 
reality
• Conduct population size estimation studies
Exclusion of foreign migrant workers, military personnel, 
refugees, and street children from HIV surveillance programs
• Commitment to fund and conduct consistent and frequent surveillance surveys
Ongoing conflicts leading to forced displacement of the 
population
• Scaling up outreach programs to reach the refugee and displaced population
Policy-making dilemmas in funding HIV research
• Combating HIV-related stigma and discrimination at individual, community, and 
structural-levels
• Coordination between ministries of health, religious leaders, and criminal justice 
system
Limited national research budgets
• Further financial support from international organizations as well as from wealthy 
countries in MENA not facing political unrests
• Establishment of a regional funding resource to share the financial burden of 
responding to HIV
Lack of publicly available databases
• Developing regional data sharing policies and publicly available databases to 
improve data access for foreign researchers and promote international and regional 
collaborations
Limited human capital • Training a generation of young local or regional HIV researchers
Abbreviation: MENA, Middle East and North.
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limited (ie, less than 2% of the global HIV literature) and 
several findings are unpublished, and large databases remain 
unanalyzed and inaccessible.7,29 
Fortunately, despite the undeniable existing socio-cultural 
barriers, most regional public health officials and policy-
makers have started to show interest in addressing the issue. 
The development of the Arab AIDS Strategy in 2014 is a 
testimony to the socio-political will of 22 Arab countries in 
working towards an AIDS-Free Generation in Arab countries. 
Moreover, the Regional Arab Network against AIDS’s 
Memorandum of Agreement with these Arab States about the 
role of civil society in implementing the Arab AIDS Strategy 
is a step forward in recognizing the important role of civil 
society in addressing the epidemic in the region.18 Although 
these initiatives are impressive and set the ground for sharing 
best practices across the region, some believe that there is 
still room for improvement in the HIV prevention efforts of 
certain members of the Arab League in reaching the goals of 
the Arab AIDS strategy.18
Lessons Learned and Path Forward
While the MENA region is facing a rapid increase in the 
number of PLHIV across different sub-populations, it has 
a unique and real window of opportunity to optimize the 
output of interventions and avoid the future burden of HIV 
on its population (Table). Considering significant degrees 
of uncertainty around the registered and estimated HIV 
cases, it is critical to create precise estimates that provide the 
governments with a real picture of the problem. Indeed, when 
concrete and quality HIV data are presented to policy-makers 
in the MENA, they could lead to policy shifts. Several regional 
successful examples of implementation of effective risk-group 
size estimations, mapping, and HIV surveillance among key 
populations exist that could be scaled up and utilized across 
other MENA countries. In other words, success stories and 
promising culturally appropriate interventions that help 
move away from misperceptions to a sound evidence-based 
approach do exist. For example, Iran, Morocco, and Lebanon 
have successfully expanded opioid substitution therapy (OST) 
programs within their communities. Moreover, needle and 
syringe programs (NSPs) have helped increase safe injection 
practices to 70% among PWID in Iran, Lebanon, Morocco, 
and Tunisia.6,9,19,31,32 Interventions aimed at improving the 
sexual health of MSM have also shown promise where 
services take on a rights-based approach to HIV prevention 
and when civil society is enabled to provide support for the 
community. For example, 75% of MSM in Lebanon have 
reported consistent condom use and knowledge of their 
HIV status. HIV prevention efforts among FSWs have also 
demonstrated success with condom use rates as high as 80% 
among FSWs in Algeria and Lebanon.2,6,33 
As these successful experiences are not necessarily shared 
across MENA countries, establishing and supporting a 
regional network of HIV research where countries and 
researchers could share the details and challenges of 
implementing these successful regional experiences (eg, 
through regional workshops, meetings, or collaborations) 
could be highly beneficial. The Global Network of Researchers 
on HIV/AIDS in the Middle East and North Africa Region 
(GNR-MENA) which is a forum for scientific exchange, 
debate and networking for researchers involved or interested 
in the HIV response in the region, has served as a platform 
for knowledge transfer; however, the voluntary nature of 
the executive positions at GNR-MENA may have limited 
its capacity for effective action. Furthermore, developing 
regional data sharing policies and publicly available databases 
could improve data access for potential foreign researchers 
and promote regional and international collaborations; 
partnerships that could help improve the quality of research, 
help build research capacities and increase the visibility of 
HIV-related publications in the MENA. While the MENA’s 
young population could fuel the epidemic, youth could, 
indeed, serve as an opportunity for the human capital 
development and training a generation of young local HIV 
scientists could make significant contributions to high-
quality data generation in the MENA. Moreover, establishing 
regional journals that focus on HIV surveillance in the region 
could also be a viable approach in promoting HIV research 
and sharing experiences across the region.
Nonetheless, high-quality HIV research is not feasible in the 
MENA as long as profound individual-, organizational-, and 
structural-level stigmas are present at different layers of the 
society. To combat the profound systemic multi-level stigmas 
around HIV and impact public opinion, multi-sectoral and 
comprehensive upstream policies should be developed and 
implemented. All informed stakeholders from researchers 
to policy-makers and religious leaders, should proactively 
collaborate, set their differences aside, and further engage 
in exchanging ideas in a scientific and evidence-based 
environment to help develop successful HIV programs in 
the MENA. Lessons learned during the implementation of 
Kerman HIV-Friendly City – an ongoing population-level 
intervention focused on creating an HIV-stigma free city in 
Iran – are a testimony to the feasibility of reaching these goals 
and could provide insight into the implementation of anti-
stigma interventions across the region. 
Furthermore, considering the global economic crisis and 
resources drying up, and the continuing conflicts across the 
region, MENA countries need to reconsider their funding 
policies towards HIV/AIDS research and preventative 
efforts at national and regional levels; the most cost-effective 
investments should be identified. Countries facing budget 
constraints in spending on HIV research and prevention 
efforts, however, should be offered financial support from 
other regional and international organizations. In particular, 
some countries in the MENA have the wealth, capacity, 
and resources tto taking HIV spending to another level 
both inside and outside their countries. Wealthy countries 
in the MENA not facing political unrests could contribute 
further by establishing a regional funding resource to share 
the financial burden of responding to HIV and help further 
scale up outreach programs reach people living in refugee 
camps and collect data on the status of PLHIV and vulnerable 
population.1,18 MENA’s leaders and policy-makers should be 
aware and act upon the fact that HIV will not stop at countries’ 
borders and could affect all countries in the region. 
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